Aims: Pelvic lymph node (PLN) radiotherapy for high-risk prostate cancer is limited by late gastrointestinal toxicity. Application of rectal and bowel constraints may reduce risks of side-effects. We evaluated associations between intensity-modulated radiotherapy (IMRT) dose-volume data and long-term gastrointestinal toxicity. Materials and methods: Data from a single-centre dose-escalation trial of PLN-IMRT were analysed, including conventionally fractionated (CFRT) and hypofractionated (HFRT) radiotherapy schedules. Associations between volumes of rectum and bowel receiving specified doses and clinician-and patient-reported toxicity outcomes were investigated independently. A metric, d median (dM), was defined as the difference in the medians of a volume between groups with and without toxicity at a specified dose and was used to test for statistically significant differences. Results: Constraints were respected in most patients and, when exceeded, led to higher rates of gastrointestinal toxicity. Biologically relevant associations between rectum dose-points and toxicity were more numerous with both mild and moderate toxicity thresholds, but statistical significance was limited after correction for false discovery rate. Rectal V50Gy (CFRT) associated with grade 2þ bleeding; bowel V43Gy and V47 (HFRT/4 days/week schedule) associated with patient-reported loose stools and diarrhoea, respectively. Further investigation showed that CFRT patients with rectal bleeding had a mean rectal V50Gy above the treatment planning constraint. Conclusions: When dose-volume parameters are kept below tight constraints, toxicity is low. Residual dosimetry loses much of its predictive power for gastrointestinal toxicity in the setting of PLN-IMRT for prostate cancer. We have benchmarked dose-volume constraints for safely delivering PLN-IMRT using CFRT or HFRT.
Introduction
Long-term side-effects can become major issues for patients in whom prostate cancer (PCa) is controlled or cured.
Late toxicity, starting 3 months to years after treatment, is of particular concern as pelvic lymph node (PLN) radiotherapy may increase gastrointestinal side-effects [1e4] .
The risk of gastrointestinal toxicity is judged with dosevolume histograms. However, there is limited consensus regarding their prognostic value, particularly in the era of dose-volume constraint-based inverse-planned radiotherapy. Although concordant at higher doses, studies show different dose-volume histogram metrics as predictive of rectal bleeding and it is difficult to find consistent correlations with other gastrointestinal symptoms [5e8] . Treatment planning dose constraints have been developed to minimise risks. Although the QUANTEC meta-analyses on gastrointestinal dose constraints provided evidence-based guidance for radiotherapy planning, they were based on studies using three-dimensional conformal radiotherapy [5, 9] . Intensity-modulated radiotherapy (IMRT) may have changed toxicity patterns and relationships with dosimetry [5, 9] . Other proposed models of risk evaluation have not been introduced in the clinic [10e12] .
We investigated relationships between dose-volume constraints and late gastrointestinal toxicity in patients prospectively treated with conventionally fractionated (CFRT) or hypofractionated (HFRT) prostate and pelvic IMRT for high-risk PCa in a phase I/II study [3] .
Materials and methods

Patients and Data
Patients treated in a previously reported phase I/II study of prostate and pelvic IMRT for high-risk PCa (IMRT-PCa trial) were eligible [3] . The trial accrued 473 patients with high-risk PCa between August 2000 and September 2013. CFRT was delivered to the prostate and seminal vesicles (70e74 Gy in 35e37 fractions) and 50, 55 or 60 Gy to the PLN concomitantly over 7e7.4 weeks. Two further cohorts received HFRT, with 60 Gy (20 fractions) delivered to the prostate and seminal vesicles and 47 Gy to the PLN in either 4 (5 days/week, HFRT-5D) or 5 weeks (4 days/week, HFRT-4D). The change to a 5 week schedule (which is an extension of the 4 week schedule to 5 weeks by delivering four instead of five fractions/week) occurred because of documented increases in short-lasting acute gastrointestinal toxicity also observed in other studies [3, 13, 14] . All patients received long-course androgen deprivation therapy.
Only patients with both toxicity and complete dosimetric data were included. Patients with <2 years of follow-up data at the time of analysis were excluded.
Dosimetric Variables
Dosimetric data were obtained from prostate and pelvic node radiotherapy forms, used to assess the clinical suitability of radiotherapy plans according to defined dose constraints (see supplementary Table SUPP-1) . Where unavailable, data were obtained from original treatment plans. Optimal and mandatory bowel constraints were derived from dose levels related to Radiation Therapy Oncology Group (RTOG) grade !1 and !2 in previous reports [15] . Rectal dose constraints were derived by pragmatically adapting available evidence at the time of study design [16, 17] . Constraints were modified for HFRT in proportion to the prescribed dose.
Rectum and bowel were contoured as solid organs according to a previously published protocol (see supplementary text) [3] . Data consisted of absolute rectum and bowel volumes (cm 3 ), and volumes of bowel (cm 3 ) and rectum (% of volume) receiving the constraint dose or higher, henceforth referred to as (a)V(x), where (x) is the respective dose (Gy) and (a) the identifier for rectum (r) or bowel (b).
Radiation-induced Gastrointestinal Toxicity Data
Clinical data were collected at 6-month intervals up to 5 years after radiotherapy and yearly thereafter. Only data collected !6 months after radiotherapy were used. In order to capture a comprehensive record of toxicity, three internationally accepted toxicity scales were used [18] . They were the European Organization for Research and Treatment of Cancer (EORTC)/RTOG and the Late Effects Normal Tissue Task Force-Subjective, Objective, Management, Analytic (LENT-SOMA) clinician-reported late toxicity scales and the UCLA Prostate Cancer Index (UCLA-PCI) patientreported outcomes scaleebowel subset (questions 17e21) [19e21] .
Analysis was undertaken endpoint-by-endpoint. Patients with positive baseline side-effect scores were excluded from analysis for that specific endpoint only. For example, if a patient had rectal bleeding before radiotherapy, he was excluded from the rectal bleeding analysis but not from tenesmus and other endpoints. We also excluded toxicity endpoints that had an incidence of 5% in the entire cohort.
Patients were divided by peak toxicity using mild and moderate/severe thresholds for each endpoint (see supplementary Table SUPP-2) [21] .
Associations were studied between dose-points and all toxicity outcomes in three different scales by cohort. We do not report amalgamated results of all cohorts given that constraints were not equivalent radiobiologically and because this strategy enables the study of differential relationships between CFRT and HFRT schedules.
Statistical Considerations
Dose-volume metrics (dose-points) where !80% of patients had a value of 0 were excluded. They were rV75/bV65 (CFRT) and rV63/bV55 (HFRT). Bowel metrics where the mean volume was <2 cm 3 were also excluded. They were bV60 (CFRT) and bV51 (HFRT).
To assess biological significance in this large dataset, a measure of inter-group difference was created. This metric, henceforth named 'd median' (dM), is defined as: Associations between dose-points and toxicity were sought by testing all dose-points against each endpoint in all toxicity scales, leading to the use of multiple statistical tests (see supplementary Table SUPP-3). The Holm method was used to correct for false discovery rate (FDR) as per the following equation [22] :
where n is the number of tested hypotheses (number of tests done by toxicity scale per cohort, including both toxicity thresholds) and the target alpha level is 0.05. It follows that all P values reported in this article are 'uncorrected', as the Holm method uses the corrected alpha level of significance as a threshold to accept or reject the null hypothesis. A positive result is defined as a positive dM (>0) where statistical significance was reached.
Where positive associations resilient to FDR correction were found, new constraints were derived using receiver operating characteristic (ROC) curves [23] . Odds ratios of toxicity were calculated for protocol and new constraints and significance assessed with Fisher's exact test.
Analysis was carried out in Excel and R [24] .
Results
Patient Characteristics
Of 473 patients recruited in the trial, 26 had been recruited <2 years before data lock and thus did not have long-term (!2 years) toxicity data available and were excluded. Of the remaining 447 patients, 426 had been treated according to protocol and long-term toxicity data were available for 421. Dosimetric data were not retrievable for seven patients and thus 414 (98% of patients with !2 year toxicity follow-up data) were included for analysis. Proportions of patients with and without toxicity were comparable with those observed in the main analysis of the IMRT for Prostate Cancer trial, except for UCLA-PCI bowel problem (see supplementary Table SUPP-4). This discrepancy is explained by our methodology, as patients with a moderate/severe bowel problem at baseline (i.e. before the start of radiotherapy) were excluded in an endpoint-byendpoint basis to obtain an accurate representation of gastrointestinal problems caused by radiotherapy. However, all patient-and clinician-reported gastrointestinal toxicity rates are comparable to previously reported analogous studies [25] .
Groups were reported by prostate radiotherapy fractionation (Table 1) because dose-volume constraints were not equivalent radiobiologically [26] . This approach allows a comparison of differences between CFRT and HFRT in terms of relationships between dosimetry and toxicity, which was one of our objectives.
Alpha level of significance ¼
Target alpha level n À rank number of pair by degree of significance þ 1 CFRT, conventionally fractionated radiotherapy; HFRT-4D, hypofractionated radiotherapy (4 days/week); HFRT-5D, hypofractionated radiotherapy (5 days/week); RTOG, Radiation Therapy Oncology Group; PLN, pelvic lymph nodes; IQR, interquartile range. LENT-SOMA. UCLA-PCI.
* Patients had planned dose reductions due to difficulties in meeting dose-volume constraints.
Number of Patients Failing Constraints and Relationships with Toxicity
We previously published encouraging toxicity outcomes of dose-escalated and hypofractionated PLN-IMRT in the IMRT for Prostate Cancer trial [3] . The trial protocol used strict dose-volume constraints for rectum and bowel (see supplementary Table SUPP-1). Application of dose-volume constraints may reduce gastrointestinal toxicity [27] . We therefore first hypothesised that rates of patients failing constraints were low in our dataset. We also explored relationships between the number of failed constraints and RTOG-scored maximum peak toxicity.
Rectum
Most patients met all constraints in all cohorts ( Figure 1A Tables SUPP5eSUPP-7) . However, the rV50 constraint was exceeded in 26% in the CFRT cohort. Patients exceeding rectal constraints experienced more toxicity, particularly with CFRT, but this pattern was also reproduced in other cohorts ( Figure 1D ).
Bowel
Optimal/mandatory bowel constraints were defined by average volumes correlating with no/mild diarrhoea, respectively, in previous reports [15] . Although optimal constraints were exceeded frequently, mandatory constraints were generally respected ( Figure 1B As with rectum, a pattern whereby patients exceeding bowel constraints experience more toxicity was observed. This pattern was most evident in the CFRT cohort and mandatory constraints ( Figure 1E, F) .
Associations between Dosimetric Parameters and Toxicity
We used the dM measure to assess differences in volumes between groups of patients with and without toxicity and assessed their statistical significance stringently. For most endpoints, dM was small: 79% and 74.6% of dM were AE3% of rectum or 10 cm 3 of bowel volumes, respectively (supplementary Table SUPP , bowel mandatory (E) and optimal (F) constraints exceeded; by cohort. Gastrointestinal toxicity was scored with maximum peak cumulative Radiation Therapy Oncology Group (RTOG) grade (rectum: maximum score of bowel frequency, bleeding, diarrhoea, proctitis, rectal stricture, rectal ulcer; bowel: maximum score of bowel frequency, diarrhoea, bowel obstruction).
All relevant results are described in Table 2 (rectum) and 3 (bowel). Supplementary Tables R1e9 (rectum) and B1e9 (bowel) summarise all findings.
Rectum
In the CFRT cohort, rV50 was higher in patients with moderate/severe (grade 2þ) rectal bleeding in both RTOG (P ¼ 0.00008) and LENT-SOMA (P ¼ 0.00004) scales. These were the only results for rectum that were resilient to Holm correction (Table 2 ). rV50 was also higher in patients with mild (grade 1þ) LENT-SOMA bleeding and bowel problem, albeit non-significantly. In HFRT cohorts, rV51/rV55 (HFRT-4D) and rV59 (HFRT-5D) associated with bleeding, albeit non-significantly.
Bowel
In the HFRT-4D cohort, bV43 and bV47 were higher in patients with mild self-reported loose stools (P ¼ 0.0005) and RTOG-scored diarrhoea (P ¼ 0.002), respectively. These were the only results resilient to FDR correction (Table 3) . However, bV39 also associated non-significantly with mild self-reported loose stools and bV43 also associated nonsignificantly with diarrhoea-related toxicity endpoints, as did bV39/bV43 and bV45/bV55/bV60 in the HFRT-5D and CFRT cohorts, respectively.
Relationships between Significant Associations and Dosevolume Constraints
Three significant associations were detected in our dataset: rV50 (CFRT) and rectal bleeding, as well as bV43/ bV47 (HFRT4D) with loose stools/diarrhoea. We examined if relationships with constraints were present and explored whether different constraints could be derived from our dataset.
CFRT/rV50 and rectal bleeding
Mean rV50 was 65%/54% and 66%/54% for patients treated with CFRT with/without grade 2þ RTOG and LENT-SOMA bleeding, respectively. Interestingly, in both cases, mean rV50 for patients with bleeding was above the rV50 constraint (Figure 2AeF ). Such a relationship was not observed for any other rectal endpoint in relation to bleeding in any cohort. The rV50-CFRT constraint derived using this dataset was 59% (AUC: 0.79; 95% confidence interval 0.69e0.89; supplementary Table SUPP-12). Odds ratios for toxicity using protocol or new constraints were similar (supplementary Table SUPP-13), indicating that the protocol constraint was adequate for preventing toxicity if respected.
HFRT-4D/bV43 and loose stools
Although mean bV43 was higher in patients with mild self-reported loose stools (36.9 cm 3 ) than in patients without loose stools (34.3 cm 3 ), they were both under the mandatory (110 cm 3 ) and over the optimal (17 cm 3 ) constraints ( Figure 2GeI ). bV39 was non-significantly higher than mandatory constraints in patients with loose stools, unlike patients without loose stools. Mean volumes for bV47ebV55 overlapped between groups, similar to the HFRT-5D cohort. With CFRT, there were no differences between groups. The bV43-HFRT constraint derived using this dataset was 24 
Discussion
Late gastrointestinal toxicity limits high-dose pelvic radiotherapy. Rectum and bowel dose-volume constraints, designed to minimise gastrointestinal side-effects, are increasingly important as inverse-planned IMRT becomes the primary radiotherapy technique for PCa. Several efforts have been made to detect thresholds below which probabilities of gastrointestinal toxicity are low [5,9,16,17,27e29] .
We acknowledge limitations in our study. Planning computed tomography is a snapshot of a moving organ, especially for non-rectal bowel. By contouring bowel loops proximal to the rectum, different organs are included (sigmoid, colon, jejunum/ileum). However, although segmented bowel outlining is increasingly used in research and has been adopted by some centres, RTOG guidelines recommend that whole bowel (i.e. unsegmented) should be outlined for genitourinary tumours, reflecting general clinical practice [30] . We also recognise that the pelvic doses studied are non-standard, as we used data derived from an IMRT dose-escalation trial [3] . However, PLN-IMRT may become a standard option pending definitive results of ongoing phase III trials. Irrespective of this, our analysis allows an understanding of modern relationships between dosimetry and toxicity in a mature dataset.
Our approach makes comparisons between fractionation schedules possible, which was one of our objectives. However, in practice, it would be imprecise to pool all cohorts into a single dose-equivalent dataset, due to three factors:
(1) a/b ratios are not available for most of the symptoms we studied, (2) there could be imprecisions related to time factors related to repair/recovery, (3) dose-points were not radiobiologically equivalent if using a 'one-fits-all' late effect a/b ratio of 3 Gy [31] .
Numbers of patients with late grade 2þ toxicity were low. For completeness, comparisons using mild toxicity thresholds were carried out in parallel. Multiple statistical tests were used, therefore requiring FDR correction. Holm correction was chosen for its robustness. We nevertheless pragmatically report different levels of significance. Overall, few results were found to be robustly significant.
We show a relationship between the number of exceeded rectal constraints and late toxicity. Our results confirm previous reports showing rV50 to predict grade 2þ rectal bleeding. However, robust relationships of higher doses 
Where N/A is reported, no positive associations were found. Where P 0.01, results are in bold. Where results were significant after Holm correction, results are bold and italicized. M ¼ mild threshold (symptomatic patients are defined as having mild or worse symptoms). MS ¼ moderate/severe (symptomatic patients are defined as having moderate or worse symptoms). % of patients with toxicity events excludes patients where data was unavailable (for full results see supplementary Tables R1eR9). (!rV65) with bleeding were not found, as might have been expected from previous reports [16, 27, 29] . Rectal dosimetry was mostly kept under constraints and specific attention was given to higher dose-points, reflecting QUANTEC guidance [5] . The fact that the lower rectal constraint (rV50) was exceeded more often with CFRT is probably due to the superior rectum receiving dose from pelvic irradiation, which was 60 Gy for the majority (67%) of patients. HFRT cohorts received 47 Gy to the PLN, which is equivalent to 55
Gy for an a/b ratio typical of late reactions (3 Gy). This aspect may also explain lower incidences of patients failing constraints with HFRT. bV43 and bV47 were significantly predictive of diarrhoeal endpoints in the HFRT-4D cohort. Although nonsignificant after FDR correction, similar trends were observed in other cohorts with clinician-reported diarrhoea. The number of mandatory and/or optimal bowel constraints exceeded showed a relationship with toxicity. A study analysing the prognostic value of bowel dose-volume metrics for acute bowel toxicity in patients undergoing prostate and pelvic radiotherapy for high-risk PCa showed bV40-bV50 to be predictive with CFRT, whereas higher (bV55) and lower (bV15) dose-points were less predictive. Interestingly, derived constraints were similar to the ones we propose, although a whole intestinal cavity contouring method was used [32] . Other studies also showed similar results [33, 34] . Robust dosimetric relationships with late toxicity have proved more elusive, but, to our knowledge, we report the largest prospectively collected patient series to date [35, 36] . Taken together, these data support the mandatory threshold as a relevant dose limit when planning pelvic radiotherapy to avoid grade 2þ diarrhoea. However, we also observed a relationship between exceeding optimal constraints and toxicity. We therefore recommend using optimal constraints as target doses and planning objectives for pelvic IMRT to ensure minimal gastrointestinal toxicity and that mandatory constraints should not be compromised to ensure acceptable gastrointestinal side-effect rates. We propose that the optimal bV50-CFRT/bV43-HFRT constraint should be updated to 24 cm 3 instead of 17 cm 3 given our results showing this level to be more appropriate for predicting gastrointestinal sideeffects. These new findings may usefully inform clinical trials and non-trial clinical practice. We previously showed that moderate/severe gastrointestinal toxicity was reported in about a third of patients meeting rectal constraints, whereas no gastrointestinal side-effects were reported in 10% of patients failing six or more constraints [27] . We observed similar relationships in this dataset. In addition to uncertainties in reporting dosimetry and toxicity, this result may be attributed to patient-related and environmental factors [37e41]. Moreover, as many as 50% of patients have multiple gastrointestinal diagnoses when symptoms, which may be misattributed to radiotherapy, are investigated [18] .
Our data support that, when dose-volume parameters are kept below tight constraints, gastrointestinal toxicity is low and planning dosimetry loses predictive power for residual moderate/severe gastrointestinal toxicities in the setting of PLN-IMRT. This conclusion suggests that if not escalating radiation dose, further technical development of radiotherapy for PCa may only achieve marginal improvements in gastrointestinal toxicity outcomes unless it reduces the rates of patients where constraints are exceeded. Future research needs to also incorporate contributing biological mechanisms of radiation-induced toxicity, which may help achieve superior clinical stratification of patients at risk of significant side-effects, as suggested by other authors.
To conclude, we provide an evidence base for safely delivering PLN-IMRT using CFRT or HFRT. We propose the constraints summarised in Table 4 as benchmarks for CFRT and HFRT and that the planning goal should be to achieve the target (optimal) bowel constraints whenever possible. * Constraints for the 3Gy cohorts were simply extrapolated from the 2Gy cohort in a ratio of 60/70 (reflecting the initial prostate treatment dose of 70Gy) with no implicit radiobiological assumptions.
